Kreatech to supply REPEAT-FREE™ DNA FISH probes for U.S. National Lung Study Durham, NC – March 7, 2013 – KREATECH, Inc., the US subsidiary of KREATECH Diagnostics (Amsterdam, The Netherlands), announced they have signed an agreement with the Lung Cancer Mutation Consortium (LCMC) allowing LCMC study sites to use KREATECH’s REPEAT-FREE™ POSEIDON™ Fluorescent In-Situ Hybridization (FISH) Probes to help identify molecular (DNA) changes in study samples. The Lung Cancer Mutation Consortium (LCMC) represents the largest initiative in the U.S. to prospectively examine non-small cell lung cancer tumors for molecular changes that have been linked with patient response to available therapies. The LCMC is providing critical genetic information on the biological profile of each patient’s tumor to allow patients to join clinical trials directed at their particular tumor profile. As more and more cancer therapies become focused on particular tumor profiles, such information will increase the ability to test new therapies designed to improve outcomes for patients. KREATECH will supply REPEAT-FREE™ POSEIDON™ DNA FISH Probes to participating LCMC labs for testing genetic aberrations of ROS1, RET, ALK and MET in the Study. KREATECH will also provide technical support for the evaluation, validation and clinical trial testing of the probes used in LCMC participating labs. “We are grateful for Kreatech’s support of the Lung Cancer Mutation Consortium,” said Regina Vidaver, Executive Director of the National Lung Cancer Partnership, the organization administering the LCMC. “This support will help doctors evaluate tumors and quickly get patients the best possible treatment”. “We are pleased to be able to support this important study evaluating the molecular changes in lung cancer. Studies such as this will hopefully lead to a better understanding of how such changes can be used to optimize the treatment of this disease which each year claims the lives of over 150,000 individuals in the U.S. alone,” says Harry Schrickx, President of KREATECH, Inc. About Lung Cancer Mutation Consortium The Lung Cancer Mutation Consortium (LCMC) represents the largest national initiative to prospectively examine non-small cell lung cancer tumors, and match patients to the best possible therapies. Currently, the LCMC includes 16 leading cancer centers across the USA. The LCMC is coordinated by a cross-institutional group of researchers and the National Lung Cancer Partnership. Find out more at www.golcmc.com and www.ClinicalTrials.gov Contact details: Regina Vidaver, Ph.D., Executive Director Ertvan@angvbanyyhatpnaprecnegarefuvc.bet P: +1-608.828.8830 About Kreatech Diagnostics: KREATECH Diagnostics is a Molecular Diagnostics company focusing on the development and worldwide commercialization of innovative detection products. KREATECH’s product portfolio enables customers to detect genetic aberrations that may lead to cancer or other diseases. KREATECH offers the broadest commercial portfolio of DNA-FISH probes available in the industry: more than 450 REPEATFREE ™ POSEIDON™ FISH probes. The REPEAT-FREE™ technology eliminates the use of Cot-1 or blocking DNA, providing less background and a brighter signal which are important features for FISH as a diagnostic and research tool. In addition, KREATECH has a dedicated portfolio for (microarray) labeling applications using its proprietary non-enzymatic Universal Linkage System (ULS™) labeling technology. KREATECH Diagnostics has commercial operations both in Europe and North America. For more information, please visit www.kreatech.com Contact details: Harry Schrickx, President Kreatech Inc. u.fpuevpxk@xerngrpu.pbz P: +1-919-949-3606